Jane Street Group, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Jane Street Group, LLC

$444 Billion
Q4 2024

A detailed history of Jane Street Group, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 656,256 shares of ARWR stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

656,256

Previous 463,880 41.47%

Holding current value

$11.4 Million

Previous $8.98 Million 37.38%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$17.7 - $26.34 $3.41 Million - $5.07 Million	192,376 Added 41.47%	656,256 $12.3 Million
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $4.51 Million - $6.88 Million	-232,839 Reduced 33.42%	463,880 $8.98 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $12.4 Million - $16.1 Million	568,647 Added 444.01%	696,719 $18.1 Million
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $1.23 Million - $1.78 Million	45,041 Added 54.25%	128,072 $3.66 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $868,606 - $1.27 Million	-40,972 Reduced 33.04%	83,031 $2.54 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $693,592 - $955,145	26,473 Added 27.14%	124,003 $3.33 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $554,350 - $911,725	22,033 Added 29.18%	97,530 $3.48 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $1.21 Million - $1.96 Million	50,897 Added 206.9%	75,497 $1.92 Million
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $325,024 - $470,820	-11,608 Reduced 32.06%	24,600 $997,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $1.26 Million - $2.06 Million	-42,570 Reduced 54.04%	36,208 $1.3 Million
Q2 2022 Aug 16, 2022	BUY	$27.79 - $50.61 $159,153 - $289,843	5,727 Added 7.84%	78,778 $2.88 Million
Q1 2022 May 17, 2022	BUY	$39.62 - $69.97 $2.04 Million - $3.6 Million	51,488 Added 238.78%	73,051 $3.36 Million
Q4 2021 Feb 15, 2022	SELL	$58.09 - $82.51 $2.12 Million - $3.01 Million	-36,449 Reduced 62.83%	21,563 $1.43 Million
Q3 2021 Nov 16, 2021	SELL	$58.38 - $84.96 $1.38 Million - $2.01 Million	-23,692 Reduced 29.0%	58,012 $3.62 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $4.12 Million - $5.98 Million	66,217 Added 427.57%	81,704 $6.77 Million
Q1 2021 May 18, 2021	SELL	$61.35 - $90.47 $1.68 Million - $2.47 Million	-27,334 Reduced 63.83%	15,487 $1.03 Million
Q4 2020 Feb 17, 2021	SELL	$43.82 - $85.37 $2.56 Million - $4.98 Million	-58,377 Reduced 57.69%	42,821 $3.29 Million
Q3 2020 Nov 17, 2020	BUY	$33.21 - $51.27 $2.69 Million - $4.16 Million	81,091 Added 403.3%	101,198 $4.36 Million
Q2 2020 Aug 17, 2020	BUY	$26.12 - $43.27 $335,015 - $554,981	12,826 Added 176.16%	20,107 $868,000
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $451,908 - $1.39 Million	-21,980 Reduced 75.12%	7,281 $209,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $196,445 - $509,682	6,981 Added 31.33%	29,261 $1.86 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $585,072 - $776,680	22,280 New	22,280 $628,000
Q2 2019 Aug 15, 2019	SELL	$17.43 - $28.82 $802,686 - $1.33 Million	-46,052 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$12.05 - $20.18 $357,487 - $598,680	29,667 Added 181.06%	46,052 $845,000
Q4 2018 Feb 15, 2019	BUY	$10.74 - $19.7 $175,974 - $322,784	16,385 New	16,385 $204,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $465,906 - $675,563	-33,279 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$6.37 - $14.02 $211,987 - $466,571	33,279 New	33,279 $453,000
Q1 2018 May 15, 2018	SELL	$3.72 - $7.64 $131,312 - $269,684	-35,299 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$3.14 - $4.5 $110,838 - $158,845	35,299	35,299 $130,000

Others Institutions Holding ARWR

# of Institutions

305

Shares Held

95.9M

Call Options Held

523K

Put Options Held

493K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.84B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Arrowhead Pharmaceuticals, Inc. Transaction History